Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Active, not recruiting Phase 2 Interventional

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

NCT03513562
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Ibrutinib Resistance
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Venetoclax
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

NCT00786669
View directory record Official record
Conditions
Solid Tumor
Interventions
Bevacizumab, Temozolomide, Vincristine, Irinotecan, Cefixime
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Simulation-based Training for Nurses and Arteriovenous Fistula Puncture in Chronic Hemodialysis Patients

NCT05302505
View directory record Official record
Conditions
Nursing Caries, Arteriovenous Fistula, Simulation-based Training
Interventions
simulation-based training
Other
Lead sponsor
University Hospital, Caen
Other
Eligibility
18 Years and older
Enrollment
9,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 25, 2026, 3:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

NCT03811002
View directory record Official record
Conditions
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Etoposide, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
532
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 400 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 25, 2026, 3:14 AM EDT
Completed No phase listed Observational Results available

Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)

NCT02073331
View directory record Official record
Conditions
Coronary Disease
Interventions
Not listed
Lead sponsor
Elutia Inc.
Industry
Eligibility
Not listed
Enrollment
1,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 25, 2026, 3:14 AM EDT
Terminated Phase 4 Interventional Results available

Fycompa in Catamenial Epilepsy

NCT05201703
View directory record Official record
Conditions
Catamenial Epilepsy
Interventions
Fycompa, Fycompa with a boost
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 25, 2026, 3:14 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

NCT02736656
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
16
States / cities
Little Rock, Arkansas • Long Beach, California • Colorado Springs, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Early Phase 1 Interventional Results available

Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD

NCT04167189
View directory record Official record
Conditions
ADHD
Interventions
Lidocaine gel
Drug
Lead sponsor
PhenoSolve, LLC
Industry
Eligibility
7 Years to 49 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 25, 2026, 3:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Pilot Study of a Remote ADHD Monitoring Program

NCT06743425
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder, ADHD
Interventions
RAMP Reports, Digital Education Handouts
Other
Lead sponsor
IDeA States Pediatric Clinical Trials Network
Network
Eligibility
5 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Jackson, Mississippi • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

NCT04940624
View directory record Official record
Conditions
Dravet Syndrome (DS)
Interventions
Soticlestat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 21 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 3:14 AM EDT
Terminated No phase listed Observational

EndoPredict® Extended Endocrine Trial (EXET)

NCT04016935
View directory record Official record
Conditions
Primary Invasive Breast Cancer
Interventions
Observational
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Burbank, California • Roseville, California • Fort Myers, Florida + 40 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

NCT01196390
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
Drug · Other · Radiation + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
634
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

AiDing Diuresis wIth Tolvaptan (ADD-IT)

NCT02646540
View directory record Official record
Conditions
Cardiomyopathy, Congestive Heart Failure
Interventions
Tolvaptan 30 mg + IV Diuretics, Metolazone 5 mg + IV Diuretics, 2.5 times the Diuretics Dose
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 25, 2026, 3:14 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
304
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 227 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Phase 3 Interventional

Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

NCT00150410
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
88
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2008 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

NCT00655876
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, cisplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 74 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
173
States / cities
Tucson, Arizona • Auburn, California • Cameron Park, California + 140 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 25, 2026, 3:14 AM EDT
Terminated Phase 4 Interventional Results available

Erector Spinae Block for Spine Surgery

NCT05417113
View directory record Official record
Conditions
Lumbar Radiculopathy
Interventions
Liposomal bupivacaine, Bupivacaine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 25, 2026, 3:14 AM EDT
Withdrawn Phase 4 Interventional

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

NCT03626376
View directory record Official record
Conditions
Herpes Simplex Virus Keratitis
Interventions
oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 25, 2026, 3:14 AM EDT
Active, not recruiting Phase 4 Interventional

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

NCT05220358
View directory record Official record
Conditions
HIV-1-infection
Interventions
Fostemsavir 600 MG [Rukobia]
Drug
Lead sponsor
Orlando Immunology Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Neuroimaging of Diet in ADHD: Phase I

NCT01862484
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Restricted Diet, Ruse Diet
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
9 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Osmotic-Release Methylphenidate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Early Phase 1 Interventional Results available

Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)

NCT01388530
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
EMS 7500 Digital Muscle Stimulator
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

The Bladder Instillation Comparison Study

NCT02695771
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Mitomycin C, Gemcitabine
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 25, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Organizational Skills Interventions for Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01176136
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Homework, Organization, and Planning Skills (HOPS) Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 25, 2026, 3:14 AM EDT